INT155822

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 3.74
Pain Relevance 0.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ADH1A) small molecule metabolic process (ADH1A) oxidoreductase activity (ADH1A)
cytoplasm (ADH1A)
Anatomy Link Frequency
urine 2
renal tubule 1
ADH1A (Homo sapiens)
Pain Link Frequency Relevance Heat
alcohol 3 97.48 Very High Very High Very High
corticosteroid 1 96.98 Very High Very High Very High
anakinra 1 96.56 Very High Very High Very High
aspirin 1 96.20 Very High Very High Very High
Eae 80 73.04 Quite High
Duloxetine 1 72.60 Quite High
withdrawal 5 40.04 Quite Low
pregabalin 1 28.60 Quite Low
headache 4 11.16 Low Low
adenocard 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyponatremia 30 99.92 Very High Very High Very High
Syndrome 2 99.64 Very High Very High Very High
Disease 13 99.00 Very High Very High Very High
Overactive Bladder 304 98.96 Very High Very High Very High
Iron Overload 1 98.26 Very High Very High Very High
Liver Disease 1 97.30 Very High Very High Very High
Schizophrenia 37 86.56 High High
Diuresis 16 82.32 Quite High
Hepatitis B Virus Infection 1 74.16 Quite High
Fatigue 5 71.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Reduced levels of UA are seen with a variety of medications (allopurinol, aspirin, probenacid, coumadin, corticosteroids), liver disease, alcohol use, Wilson's disease, hemochromatosis, protein or purine deficiency, xanthine oxidase deficiency, syndrome of inappropriate ADH secretion (SIADH) or renal tubule disease [58].
Localization (secretion) of ADH in renal tubule associated with hyponatremia, aspirin, corticosteroid, syndrome, iron overload, disease, alcohol and liver disease
1) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2831068 Disease Relevance 1.10 Pain Relevance 0.15
However, in another study to investigate the effects of long-term oral desmopressin on baseline ADH secretion in elderly patients with nocturia, administration of desmopressin for 1 yr in elderly patients did not affect baseline ADH secretion in spite of significantly decreasing nocturnal urine output and the number of nocturia episodes (P<0.01) (27).
Localization (secretion) of ADH in urine associated with overactive bladder
2) Confidence 0.78 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2995235 Disease Relevance 0.48 Pain Relevance 0
However, in another study to investigate the effects of long-term oral desmopressin on baseline ADH secretion in elderly patients with nocturia, administration of desmopressin for 1 yr in elderly patients did not affect baseline ADH secretion in spite of significantly decreasing nocturnal urine output and the number of nocturia episodes (P<0.01) (27).
Localization (secretion) of ADH in urine associated with overactive bladder
3) Confidence 0.78 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2995235 Disease Relevance 0.60 Pain Relevance 0
It seems that not only spontaneous sleep, but also less fragmented sleep with undisturbed sleep duration, and deep stages of sleep with a decreased nocturnal voiding frequency improve after desmopressin treatment as a result of the effects of endogenous in vivo ADH secretion on NU.
Localization (secretion) of ADH associated with overactive bladder
4) Confidence 0.78 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2995235 Disease Relevance 0.40 Pain Relevance 0
Oral desmopressin, is effective against NP because it compensates for loss of circadian rhythm-related ADH secretion and furthermore, it causes slight changes in drinking habits.
Localization (secretion) of ADH associated with overactive bladder
5) Confidence 0.78 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2995235 Disease Relevance 1.09 Pain Relevance 0.09
The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Perillyl alcohol, Perphenazine 4-aminobutyrate, PeviPRO/breast cancer, PF-03814735, PHA-739358, Pimecrolimus, Plitidepsin, Posaconazole, Prasterone, Prasugrel, Pregabalin, Prucalopride, PRX-08066; rAAV2-TNFR:Fc, Ranelic acid distrontium salt, Ranibizumab, rCD154-CLL, Retapamulin, RTS,S/SBAS2, rV-PSA-TRICOM/rF-PSA-TRICOM; SG-2000, Sinecatechins, Sirolimus-eluting stent, Sorafenib, SP-1640, Strontium malonate, Succinobucol, Sunitinib malate; Taxus, Teduglutide, Telavancin hydrochloride, Telbivudine, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ustekinumab; V-5 Immunitor, Voriconazole, Vorinostat; Xience V, XL-184, XL-647, XL-765; Y-39983, Zibotentan.
Localization (retrieved) of ADH-1 associated with pregabalin, anakinra, breast cancer, hepatitis b virus infection, duloxetine and alcohol
6) Confidence 0.29 Published 2008 Journal Methods Find Exp Clin Pharmacol Section Abstract Doc Link 18985183 Disease Relevance 0.07 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox